Resverlogix Corp. (RVX.TO)
CAD 0.05
(12.5%)
CAD 0.05
(12.5%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -12.74 Million USD | 20.18% |
| 2021 | -15.97 Million USD | -109533.14% |
| 2020 | -14.56 Thousand USD | 99.94% |
| 2019 | -22.57 Million USD | -58178.27% |
| 2018 | -38.74 Thousand USD | 99.87% |
| 2017 | -30.9 Million USD | 9.5% |
| 2016 | -34.14 Million USD | -70.66% |
| 2015 | -20 Million USD | -136.55% |
| 2014 | -8.45 Million USD | 39.74% |
| 2013 | -14.03 Million USD | 59.47% |
| 2012 | -34.63 Million USD | -39.87% |
| 2011 | -24.76 Million USD | -11.95% |
| 2010 | -22.12 Million USD | -0.19% |
| 2009 | -22.07 Million USD | -15.2% |
| 2008 | -19.16 Million USD | 22.77% |
| 2007 | -24.81 Million USD | -56.21% |
| 2006 | -15.88 Million USD | -150.12% |
| 2005 | -6.35 Million USD | -121.23% |
| 2004 | -2.87 Million USD | -106.49% |
| 2003 | -1.39 Million USD | -171.11% |
| 2002 | -512.82 Thousand USD | -1208.95% |
| 2001 | -39.17 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q1 | -1592.00 USD | 99.94% |
| 2023 Q2 | -1.44 Million USD | -90666.33% |
| 2023 Q3 | -1.1 Million USD | 23.81% |
| 2022 Q1 | -5.96 Million USD | -5.62% |
| 2022 Q2 | -2.04 Million USD | 65.7% |
| 2022 Q3 | -2.22 Million USD | -8.85% |
| 2022 FY | -12.74 Million USD | 20.18% |
| 2022 Q4 | -2.51 Million USD | -13.03% |
| 2021 Q2 | -3.45 Million USD | -109.78% |
| 2021 Q1 | -1.64 Million USD | 0.0% |
| 2021 FY | -15.97 Million USD | -109533.14% |
| 2021 Q4 | -5.64 Million USD | -7.96% |
| 2021 Q3 | -5.22 Million USD | -51.43% |
| 2020 Q3 | -1.62 Million USD | 43.91% |
| 2020 FY | -14.56 Thousand USD | 99.94% |
| 2020 Q1 | -1.63 Million USD | 67.28% |
| 2020 Q2 | -2.89 Million USD | -76.97% |
| 2019 Q4 | -4.99 Million USD | 95.73% |
| 2019 Q3 | -116.89 Million USD | -389.99% |
| 2019 Q2 | -23.85 Million USD | -154.05% |
| 2019 Q1 | 44.13 Million USD | 747.87% |
| 2019 FY | -22.57 Million USD | -58178.27% |
| 2018 Q3 | -10.9 Million USD | -133.55% |
| 2018 Q4 | -6.81 Million USD | 37.55% |
| 2018 Q1 | -12.68 Million USD | 1.6% |
| 2018 Q2 | 32.51 Million USD | 356.28% |
| 2018 FY | -38.74 Thousand USD | 99.87% |
| 2017 FY | -30.9 Million USD | 9.5% |
| 2017 Q4 | -12.89 Million USD | -34.58% |
| 2017 Q3 | -9.58 Million USD | -7.54% |
| 2017 Q2 | -8.9 Million USD | 8.8% |
| 2017 Q1 | -9.76 Million USD | -1.12% |
| 2016 Q3 | -7.59 Million USD | -6.82% |
| 2016 Q1 | -7.62 Million USD | -60.5% |
| 2016 Q2 | -7.11 Million USD | 6.66% |
| 2016 FY | -34.14 Million USD | -70.66% |
| 2016 Q4 | -9.66 Million USD | -27.14% |
| 2015 Q3 | -4.14 Million USD | -18.57% |
| 2015 Q4 | -4.74 Million USD | -14.63% |
| 2015 FY | -20 Million USD | -136.55% |
| 2015 Q2 | -3.49 Million USD | -17.92% |
| 2015 Q1 | -2.96 Million USD | -53.84% |
| 2014 Q1 | -2.92 Million USD | -56.75% |
| 2014 FY | -8.45 Million USD | 39.74% |
| 2014 Q3 | -1.8 Million USD | -2.15% |
| 2014 Q4 | -1.92 Million USD | -6.76% |
| 2014 Q2 | -1.76 Million USD | 39.62% |
| 2013 FY | -14.03 Million USD | 59.47% |
| 2013 Q3 | -2.17 Million USD | 69.24% |
| 2013 Q4 | -1.86 Million USD | 14.21% |
| 2013 Q2 | -7.07 Million USD | 24.83% |
| 2013 Q1 | -9.4 Million USD | -12.7% |
| 2012 FY | -34.63 Million USD | -39.87% |
| 2012 Q4 | -8.34 Million USD | -0.69% |
| 2012 Q3 | -8.28 Million USD | 3.62% |
| 2012 Q2 | -8.59 Million USD | -25.11% |
| 2012 Q1 | -6.87 Million USD | -25.37% |
| 2011 Q4 | -5.48 Million USD | 21.36% |
| 2011 FY | -24.76 Million USD | -11.95% |
| 2011 Q2 | -5.3 Million USD | 21.56% |
| 2011 Q3 | -6.97 Million USD | -31.4% |
| 2011 Q1 | -6.76 Million USD | -49.96% |
| 2010 Q3 | -5.31 Million USD | -0.14% |
| 2010 Q4 | -4.5 Million USD | 15.21% |
| 2010 FY | -22.12 Million USD | -0.19% |
| 2010 Q1 | -5.58 Million USD | 29.25% |
| 2010 Q2 | -5.31 Million USD | 4.82% |
| 2009 Q2 | -4.62 Million USD | -22.49% |
| 2009 Q4 | -7.88 Million USD | -102.12% |
| 2009 Q3 | -3.9 Million USD | 15.66% |
| 2009 Q1 | -3.77 Million USD | 23.08% |
| 2009 FY | -22.07 Million USD | -15.2% |
| 2008 Q3 | -4.71 Million USD | -12.32% |
| 2008 Q1 | -7.22 Million USD | -31.85% |
| 2008 Q2 | -4.2 Million USD | 41.88% |
| 2008 Q4 | -4.91 Million USD | -4.05% |
| 2008 FY | -19.16 Million USD | 22.77% |
| 2007 Q2 | -5.44 Million USD | 30.26% |
| 2007 Q4 | -5.48 Million USD | 18.0% |
| 2007 Q3 | -6.68 Million USD | -22.89% |
| 2007 Q1 | -7.8 Million USD | -109.95% |
| 2007 FY | -24.81 Million USD | -56.21% |
| 2006 FY | -15.88 Million USD | -150.12% |
| 2006 Q4 | -3.71 Million USD | -31.75% |
| 2006 Q3 | -2.82 Million USD | -60.52% |
| 2006 Q1 | -2.04 Million USD | -59.76% |
| 2006 Q2 | -1.75 Million USD | 14.18% |
| 2005 Q2 | -1.11 Million USD | -16.94% |
| 2005 FY | -6.35 Million USD | -121.23% |
| 2005 Q4 | -1.28 Million USD | 27.77% |
| 2005 Q3 | -1.77 Million USD | -59.71% |
| 2005 Q1 | -950.08 Thousand USD | -3.49% |
| 2004 Q4 | -918.04 Thousand USD | -212.74% |
| 2004 Q2 | -440.22 Thousand USD | 37.93% |
| 2004 Q1 | -709.28 Thousand USD | -204.51% |
| 2004 FY | -2.87 Million USD | -106.49% |
| 2004 Q3 | -293.55 Thousand USD | 33.32% |
| 2003 Q3 | -146.28 Thousand USD | 48.73% |
| 2003 Q2 | -285.33 Thousand USD | -14.94% |
| 2003 FY | -1.39 Million USD | -171.11% |
| 2003 Q4 | -232.92 Thousand USD | -59.23% |
| 2003 Q1 | -248.24 Thousand USD | -110.21% |
| 2002 Q3 | -12.95 Thousand USD | 49.44% |
| 2002 Q4 | -118.09 Thousand USD | -811.58% |
| 2002 FY | -512.82 Thousand USD | -1208.95% |
| 2002 Q1 | -4777.27 USD | 0.0% |
| 2002 Q2 | -25.62 Thousand USD | -436.37% |
| 2001 FY | -39.17 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Appili Therapeutics Inc. | -8.05 Million CAD | -58.369% |
| Eupraxia Pharmaceuticals Inc. | -36.89 Million CAD | 65.447% |
| Helix BioPharma Corp. | -9.37 Million CAD | -36.047% |
| Microbix Biosystems Inc. | -2.73 Million CAD | -365.899% |
| Medicenna Therapeutics Corp. | -19.66 Million CAD | 35.162% |
| Satellos Bioscience Inc. | -15.46 Million CAD | 17.552% |
| Oncolytics Biotech Inc. | -33.79 Million CAD | 62.271% |
| Sernova Corp. | -41.13 Million CAD | 69.004% |